Table 1 Demographic and clinical characteristics for the integrated treatment (IT) and treatment as usual (TAU) groups at baseline
Variables | All patients (n = 45) | IT group (n = 28) | TAU group (n = 17) | Statistics | P-value |
|---|---|---|---|---|---|
Baseline demographics | |||||
Age. Mean (SD) | 24.5 (4.5) | 25.5 (4.8) | 24.3 (4.2) | Independent t-test | .395 |
Gender. No. (%) | |||||
Female | 18 (40) | 11 (39) | 7 (41) | Chi-Square | .900 |
Male | 27 (60) | 17 (61) | 10 (59) | ||
Hospitalized before study entry. No (%) | |||||
Yes | 39 (87) | 27 (96) | 12 (71) | Fishers Exact test | .023* |
No | 6 (13) | 1 (4) | 5 (29) | ||
Days hospitalized 12 months preceding study entry. Mean (SD) | 131 (103) | 131 (105) | 131 (103) | Independent t-test | .983 |
Psychiatric assessments, baseline. | |||||
Diagnoses (DSM-IV). No. (%) | |||||
Schizophrenia | 40 (80) | 23 (76) | 17 (85) | ||
Schizoaffective | 6 (12) | 5 (17) | 1 (5) | ||
Schizophreniform | 4 (8) | 2 (7) | 2 (10) | ||
GAF score. Mean (SD) | 49.7 (10.7) | 52.0 (11.5) | 45.9 (8.3) | Independent t-test | .064 |
Total BPRS score. Mean (SD) | 39.7 (7.6) | 37.9 (7.5) | 42.6 (7.2) | Independent t-test | .046* |
Antipsychotic drugs, Chlorpromazine equivalent dose per day (mg). Mean (SD) | 229 (118) | 211 (93) | 259 (148) | Independent t-test | .185 |